AMA enters online forum with Sermo

Share this article:
The American Medical Association (AMA) announced it is partnering with Sermo, the online community for physicians.

The deal is designed to give the 160-year-old group entrée into a fast-growing online forum, which, in turn, wins access to AMA's 130,000-strong membership. Links and references to Sermo, which boasts around 16,000 members, will feature in online and offline AMA publications. Sermo members will gain access to the full text of articles featured in AMA titles, and the site's staff will work with AMA on enhancing the organization's online publications.

“We're becoming a real voice of physicians, but we're not an advocacy organization,” said
Sermo founder Dr. Daniel Palestrant. “There's one organization that does have that mandate to represent the interests of physicians, and that's the AMA.”

In addition to a ready-made online forum and assistance with site design, the AMA will gain free access to the monitoring services that Sermo charges its Wall Street clients for.

Sermo is also in talks with 10-20 pharmaceutical companies about its offering, which would allow companies to see, in anonymized form, what Sermo members are saying about their products.
Launched in September, the fast-growing site offers its physicians-only membership small cash rewards (typically $20) for particularly thoughtful postings, as ranked by their peers.  

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...